Related Experiment Video
Updated: Jan 30, 2026

07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
Aging, MicroRNAs, and Heart Failure
Current Problems in Cardiology
|February 2, 2019
Summary
Aging significantly impacts heart failure risk. This review explores age-dependent microRNAs (miRNAs) in heart failure, particularly the understudied role in preserved ejection fraction heart failure prevalent in the elderly.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Gerontology
Background:
- Aging is a primary risk factor for heart failure.
- Mechanisms of heart failure are not fully understood.
- The role of noncoding RNAs, especially microRNAs (miRNAs), in heart failure is poorly characterized.
Purpose of the Study:
- To review the role of age-dependent miRNAs in heart failure.
- To investigate the unknown role of miRNAs in heart failure with preserved ejection fraction (HFpEF).
- To examine associations between HFpEF, aging, and prevalent elderly conditions.
Main Methods:
- Literature review focusing on aging, miRNAs, and heart failure.
- Analysis of existing research on microRNA regulation in cardiac and vascular cells.
- Synthesis of data linking age-related conditions to HFpEF.
Main Results:
- MicroRNAs (miRNAs) are implicated in heart failure with reduced ejection fraction.
- The specific role of miRNAs in heart failure with preserved ejection fraction (HFpEF) remains largely unknown.
- HFpEF is the predominant form of heart failure in the elderly.
Conclusions:
- Age-dependent miRNAs are crucial in understanding heart failure.
- Further research into miRNAs is needed to elucidate mechanisms of HFpEF.
- Understanding these molecular pathways may lead to new therapeutic strategies for age-related heart conditions.
Related Concept Videos
MicroRNAs
24.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
Heart Failure II: Pathophysiology
894
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
894
Pathophysiology of Heart Failure
3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction
865
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
865
Heart Failure VI: Adjunct Therapies
329
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
329
Heart Failure Drugs: Diuretics
963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963

